Pfizer Inc. (NYSE:PFE) Stake Boosted by Wedmont Private Capital

Wedmont Private Capital boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 18.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 35,479 shares of the biopharmaceutical company’s stock after acquiring an additional 5,435 shares during the quarter. Wedmont Private Capital’s holdings in Pfizer were worth $1,026,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of PFE. Olistico Wealth LLC acquired a new stake in shares of Pfizer during the 2nd quarter valued at about $25,000. Creekmur Asset Management LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at about $32,000. Trivant Custom Portfolio Group LLC lifted its holdings in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the last quarter. Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer during the 4th quarter valued at about $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new stake in shares of Pfizer during the 4th quarter valued at about $37,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 1.5 %

NYSE PFE traded up $0.44 during trading on Tuesday, reaching $28.89. 21,144,404 shares of the stock traded hands, compared to its average volume of 39,585,695. The firm has a market cap of $163.71 billion, a price-to-earnings ratio of -480.75, a price-to-earnings-growth ratio of 1.02 and a beta of 0.69. The stock’s 50-day moving average price is $28.78 and its 200 day moving average price is $27.87. The company has a quick ratio of 0.78, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $37.19.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.67 earnings per share. Analysts predict that Pfizer Inc. will post 2.68 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.82%. The ex-dividend date is Friday, July 26th. Pfizer’s payout ratio is currently -2,799.53%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. UBS Group boosted their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Morgan Stanley boosted their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Wells Fargo & Company lifted their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Finally, StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.